Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992904 | 0.81 | RELA (0.47) | RELAALDH1A1L3MBTL1GLAEGFR | |
| SCHEMBL8923377 | 0.78 | NFE2L2 (0.52) | ALDH1A1CYP1A2TDP1 | |
| SCHEMBL16956202 | 0.75 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1GLAMAPTNPSR1 | |
| SCHEMBL3391035 | 0.75 | RELA (0.42) | RELAALDH1A1L3MBTL1GLAEGFR | |
| SCHEMBL4180647 | 0.74 | LMNA (0.48) | ALDH1A1L3MBTL1GLAMAPTNPSR1 | |
| SCHEMBL20725126 | 0.74 | ALDH1A1 (0.47) | RELAALDH1A1L3MBTL1GLAMAPT | |
| SCHEMBL16958359 | 0.74 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1GLAMAPTNPSR1 | |
| 1,2-Diethoxybenzene SCHEMBL578986 | 0.73 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1GLAMAPTNPSR1 | |
| 1,2-Diethoxybenzene SCHEMBL29428929 | 0.73 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1GLAMAPTNPSR1 | |
| SCHEMBL6930038 | 0.73 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1GLAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361225-B1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | SANKYO CO (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-7091352-B2 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1377577-B1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO CO (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1070711-B1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1377577-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | Sankyo Company Limited (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1361225-A1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | Sankyo Company, Limited (JP) | 2003-11-12 | — | — | EP | disclosed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1243589-A1 | Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | RELA 35/4885ALDH1A1 871/4885L3MBTL1 4201/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | RELA 37/4885ALDH1A1 928/4885L3MBTL1 4053/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | RELA 148/4885ALDH1A1 1023/4885L3MBTL1 4373/4885 |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | IL2, IL1B, IL4I1 | RELA 32/4885ALDH1A1 507/4885L3MBTL1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.